Relation of intermediate-conductance Ca(2+)-activated K(+) channels with ability of proliferation, migration, invasion and IgE secretion of multiple myeloma cells.
10.7534/j.issn.1009-2137.2014.03.031
- Author:
Lian-Jie WANG
1
;
Wei WANG
2
;
Shu-Ye WANG
1
;
Wan-Ting HE
1
;
Qiu ZHANG
1
;
Xiao-Xia LI
1
;
Zhi-Yu LIU
1
Author Information
1. Department of Haematology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjian Province, China.
2. Department of Haematology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjian Province, China. E-mail: ww0545@163.com.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
Cell Line, Tumor;
Cell Proliferation;
Humans;
Immunoglobulin E;
metabolism;
Multiple Myeloma;
metabolism;
pathology;
Potassium Channels, Calcium-Activated;
drug effects
- From:
Journal of Experimental Hematology
2014;22(3):742-746
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the effects of the intermediate-conductance Ca(2+)-activated K(+) (IKCa1) channels on the proliferation, migration, invasion ability and monoclonal immunoglobulin (IgE) secretion of multiple myeloma (MM) cells. Trypan blue exclusion was used to evaluate the impact of clotrimazole (CLO, an inhibitor of the KCa1) on the survival ability of MM cell line U266; transwell chamber and matrigel experiments were used to evaluate the impact of CLO on the ability of the migration and invasion of U266 cells; the influence of CLO on IgE secretion in U266 cells was detected by ELISA. The results showed that small dose of CLO ( ≤ 1.0 µmol/L) could not inhibit the viability of U266 cells. The Transwell and Matrigel invading tests displayed that the cell number moving into lower chamber of transwell decreased after U266 cells treated with small dose of CLO ( ≤ 1.0 µmol/L). After treating the cells with 1.00 µmol/L CLO for 24 h and 48 h, the concentration of IgE in cell supernatant was (4.98 ± 0.39) and (4.38 ± 0.32) ng/ml, while those in control group were (15.41 ± 1.88) and (19.73 ± 2.01) ng/ml, respectively, suggesting significant difference between them(P < 0.05). It is concluded that CLO can decrease the ability of migration and monoclonal immunoglobulin secretion of multiple myeloma cells by blocking the IKCa1, thus this study provides a new think for the targeted therapy of MM.
